author-photo

Rocio Garcia-Carbonero

Spanish National Research Council
Complutense University of Madrid

303

Papers

7601

Citations

Citation Trend

Filter By

Papers (303) Sort By

Journal Conference Others

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
P-137 Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252].

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study.

2021 Neuroendocrinology
Show All
- Source
- Cite
- Save
Citations (1)
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (4)
Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)